Clinical Trials Sponsored by Bellicum Pharmaceuticals

Total 19927 results

Bellicum Pharmaceuticals

Terminated

Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases

Hemoglobinopathies | Hemophagocytic Lymphohistiocytosis | Metabolic Disorders | Primary Immune Deficiency Disorders | Inherited Bone Marrow Failure Syndrome

United States
Bellicum Pharmaceuticals

Terminated

Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant

Lymphoma, Non-Hodgkin | Acute Lymphoblastic Leukemia | Primary Immunodeficiency | Anemia, Sickle Cell | Hemoglobinopathies | Fanconi Anemia | Anemia, Aplastic | Myelodysplastic Syndrome | Thalassemia | Cytopenia | Diamond Blackfan Anemia | Osteopetrosis | Leukemia, Acute Myeloid (AML), Child

United Kingdom, Italy
Bellicum Pharmaceuticals

Terminated

Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study

Lymphoma, Non-Hodgkin | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Primary Immunodeficiency | Anemia, Sickle Cell | Hemoglobinopathies | Fanconi Anemia | Anemia, Aplastic | Thalassemia | Cytopenia | Diamond Blackfan Anemia | Leukemia, Acute Myeloid (AML), Child

Italy
Bellicum Pharmaceuticals

Withdrawn

Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT

Myelodysplastic Syndromes | Leukemia | Multiple Myeloma | Lymphomas | Other High-risk Hematological Malignancies
Bellicum Pharmaceuticals

Withdrawn

Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies

Hematologic Malignancies

United States
Bellicum Pharmaceuticals

No longer available

BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 Study

Hurler Syndrome | Inborn Errors of Metabolism | Metachromatic Leukodystrophy | Inherited Metabolic Disorder | Lysosomal Storage Disorder

United States
Bellicum Pharmaceuticals

Suspended

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Solid Tumor, Adult | HER-2 Gene Amplification | HER-2 Protein Overexpression

United States
Bellicum Pharmaceuticals

Active, not recruiting

Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia

United States
Bellicum Pharmaceuticals

Active, not recruiting

Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant

Hematologic Malignancy

Italy
Bellicum Pharmaceuticals

Active, not recruiting

Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

Lymphoma, Non-Hodgkin | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Anemia, Aplastic | Primary Immune Deficiency Disorder | Cytopenia | Osteopetrosis | Leukemia, Acute Myeloid (AML), Child | Hemoglobinopathy in Children

United States
Bellicum Pharmaceuticals

Completed

Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer

Castrate Resistent Prostate Cancer

United States
Bellicum Pharmaceuticals

Terminated

Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Uveal Melanoma

United States
Bellicum Pharmaceuticals

Terminated

Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS (THRIVE)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Bellicum Pharmaceuticals

Suspended

Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Bellicum Pharmaceuticals

Active, not recruiting

Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Hematologic Neoplasms | Multiple Myeloma

United States
Tracon Pharmaceuticals Inc.
Janssen Pharmaceutica N.V., Belgium

Completed

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

Metastatic Castrate-resistant Prostate Cancer | Adenocarcinoma, Prostate

United States
M.D. Anderson Cancer Center
Bellicum Pharmaceuticals

Recruiting

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

Solid Tumors

United States
M.D. Anderson Cancer Center
Bellicum Pharmaceuticals

Terminated

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

Leukemia | Myeloma | Myeloproliferative Diseases

United States
UNC Lineberger Comprehensive Cancer Center
Bellicum Pharmaceuticals

Not yet recruiting

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

Breast Cancer | Triple Negative Breast Cancer | Relapse | Resistant Cancer

United States
M.D. Anderson Cancer Center
Bellicum Pharmaceuticals, Inc.

Not yet recruiting

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Colorectal Cancer | Minimal Residual Disease

United States
UNC Lineberger Comprehensive Cancer Center
Bellicum Pharmaceuticals

No longer available

Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch

Immune System Diseases | Immunoproliferative Disorders | Acute Lymphoblastic Leukemia

United States
Janssen Pharmaceutica N.V., Belgium

Withdrawn

A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment (SALMONS)

Hepatitis B, Chronic

Germany, France, Italy, Spain, Denmark, Portugal, Greece
Janssen Pharmaceutica N.V., Belgium

Completed

Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets

HIV-1

United States, Spain
Janssen Pharmaceutica N.V., Belgium

Completed

A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis (PsaBio)

Psoriatic Arthritis

France, United Kingdom, Belgium, Spain, Netherlands, Greece, Russian Federation
Janssen Pharmaceutica N.V., Belgium

Terminated

A Study to Evaluate the Effect of Renal Impairment on JNJ-64417184 and Its Two Minor Metabolites JNJ-68294291 and JNJ-65201526 in Adult Participants

Renal Impairment

Germany
Janssen Pharmaceutica N.V., Belgium

Completed

A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-64041575 in Adult Participants With Various Degrees of Renal Function

Renal Insufficiency

Germany
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain.

Pain

France, Poland, Germany, Slovenia, Sweden, Czech Republic, Norway, Slovakia, Switzerland, Denmark
Janssen Pharmaceutica N.V., Belgium

Completed

A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder

Bipolar Disorder

China, Taiwan, Colombia, India, Malaysia, Russian Federation, South Africa, Greece, Peru, Germany, Mexico, Lebanon, Indonesia, Philippines, Jordan
Janssen Pharmaceutica N.V., Belgium

Completed

Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode

Schizophrenia

United Kingdom, Slovenia, Denmark, Finland, France, Greece, Israel, Norway, Sweden, Switzerland
Janssen Pharmaceutica N.V., Belgium

Completed

Interaction Between Etravirine or Darunavir/Ritonavir and Artemether / Lumefantrine (DDI Coartem)

HIV
Janssen Pharmaceutica N.V., Belgium

Completed

A Survey Study of the Treatment and Outcome Management in Patients Diagnosed With Alzheimer's Disease

Mental Disorders | Brain Diseases | Nervous System Diseases | Dementia | Alzheimer Disease
Janssen Pharmaceutica N.V., Belgium

Completed

A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset Psychosis

Schizophrenia
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)

Psychotic Disorders | Schizophrenia
Janssen Pharmaceutica N.V., Belgium

Completed

Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study

Dementia | Alzheimer Disease
Janssen Pharmaceutica N.V., Belgium

Completed

A 15-day Study to Assess the Safety and Clinical Utility of Duragesic (Fentanyl Transdermal Patch) in the Treatment of Children With Continuous Pain Requiring Narcotic Pain Relief Therapy

Chronic Pain
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of the Effectiveness and Safety of Prolonged-release Methylphenidate Hydrochloride in Adult Patients With Attention Deficit/Hyperactivity Disorder.

Attention Deficit Disorder With Hyperactivity
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of the Effect on Pain Control of Treatment With Fentanyl, Administered Through the Skin, Compared With Placebo in Patients With Osteoarthritis

Arthritis | Osteoarthritis
Janssen Pharmaceutica N.V., Belgium

Completed

EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure

Chronic Renal Failure
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia

Dementia | Alzheimer Disease | Dementia, Vascular
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of the Effectiveness and Safety of Risperidone Versus Placebo as add-on Therapy to Mood Stabilizers, in the Treatment of Manic Episodes Associated With Bipolar Disorder.

Bipolar Disorder | Manic Disorder
Janssen Pharmaceutica N.V., Belgium

Completed

RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain Information on the Safety and Efficacy of Risperidone When Used in Routine Clinical Practice

Psychotic Disorders | Schizophrenia | Schizoaffective Disorder
Janssen Pharmaceutica N.V., Belgium

Recruiting

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma (MoMMent)

Relapsed/Refractory Multiple Myeloma

Germany, Italy, Belgium, Spain, Netherlands, France, United Kingdom
Janssen Pharmaceutica N.V., Belgium

Recruiting

A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice (PsABIOnd)

Arthritis, Psoriatic

Belgium, Korea, Republic of, Austria, Germany, Japan, Mexico, Greece, United Kingdom, Italy, Sweden, Spain, France, Taiwan, Netherlands, Canada, Argentina, Australia, Colombia, Russian Federation, Switzerland
Janssen Pharmaceutica N.V., Belgium

Completed

A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19

Critical Confirmed Coronavirus Disease (COVID)-19

United States
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy (COSMOS)

Arthritis, Psoriatic

Belgium, France, Israel, Italy, Germany, Bulgaria, Spain, Poland, Russian Federation, United Kingdom, Ukraine, Hungary, Portugal, Greece
Janssen Pharmaceutica N.V., Belgium

Completed

A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants

Healthy

Belgium
Janssen Pharmaceutica N.V., Belgium

Terminated

A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate Agents

Healthy

Netherlands
Janssen Pharmaceutica N.V., Belgium

Completed

A Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Participant-Reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Participants (AQUARiUS)

Prostatic Neoplasms

France, United Kingdom, Denmark
Janssen Pharmaceutica N.V., Belgium

Completed

Tracking Biologics Along the Silk Road (HARIR)

Arthritis, Rheumatoid; Spondylitis, Ankylosing; Arthritis, Psoriatic; Colitis, Ulcerative

Saudi Arabia, Egypt, Qatar, Algeria, Kuwait
Janssen Pharmaceutica N.V., Belgium

Completed

Clinical Assessment and Psychosocial Impact of Psoriasis (EPIDEPSO)

Psoriasis

France, United Kingdom, Spain, Belgium, Israel, Netherlands, Greece, South Africa, Russian Federation, Ireland, Austria, Norway

Clinical Trials Sponsored by Bellicum Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations